J.B. Chemicals & Pharmaceuticals Ltd.

Shareholder Meeting to Approve Amalgamation with Torrent Pharmaceuticals Ltd.

Key Dates

What is being proposed?

A Scheme of Amalgamation under Sections 230‑232 of the Companies Act, 2013, ordered by the National Company Law Tribunal (NCLT), Ahmedabad Bench.
JB Pharma (Transferor) will merge into Torrent Pharmaceuticals (Transferee). Shareholders of JB Pharma will receive Torrent shares according to a share‑exchange ratio detailed in Annexure‑6 (joint valuation report by EY and BDO).
The scheme requires approval by a majority of shareholders and subsequent sanction by the NCLT and other regulators.

Strategic Rationale

Scale & Synergy: Combined entity will have a larger product pipeline, broader distribution network, and enhanced R&D capabilities.
Cost Efficiency: Expected operational synergies and reduction of overlapping functions.
Market Position: Strengthened presence in both domestic and export markets, positioning the merged firm as a top‑tier pharmaceutical player.

Financial Implications

Detailed financials are provided in Annexures 4‑5 (unaudited standalone & consolidated statements for FY 2025). The merger is expected to improve earnings per share (EPS) post‑integration, though exact figures depend on final share‑exchange terms.
No immediate cash outflow for shareholders; the transaction is share‑based.

Regulatory & Compliance

The meeting is convened per the NCLT order; the scheme must receive final approval from the Tribunal.
Additional approvals from SEBI, BSE, NSE, and other statutory bodies are required (see Annexures 9‑12).
Independent fairness opinions (Axis Capital & ICICI Securities) and valuation reports have been obtained, supporting the fairness of the exchange ratio.

Risks & Considerations

Approval Risk: The scheme must be approved by shareholders and the NCLT. A negative vote would halt the merger.
Regulatory Delays: Pending clearances from stock exchanges and other authorities could postpone integration.
Integration Risk: Merging operations, cultures, and systems may encounter challenges, potentially affecting short‑term performance.
Dilution: Existing JB Pharma shareholders will see their ownership diluted in the combined entity.

Opportunities

Growth: Access to Torrent’s product portfolio and market channels can accelerate revenue growth.
Synergy Realisation: Cost savings and improved margins post‑integration.
Enhanced Valuation: A successful merger could lead to a re‑rating of the combined entity by analysts.

Next Steps for Investors

Review the Scheme documents (Annexures 1‑8) available on www.jbpharma.com and the CDSL e‑voting portal.
Cast your vote during the remote e‑voting window (24‑27 Apr) or during the meeting.
Monitor the outcome of the shareholder vote and subsequent NCLT approval.
Stay updated on any post‑merger integration plans and financial guidance released by the combined entity.

Prepared on 27 March 2026 for JB Pharma investors.